Terns Pharmaceuticals Inc (TERN) 52.95 USD (%)

Terns Pharmaceuticals specializes in the research and development of therapies in hepatology, particularly for the treatment of NASH.

Comment

Performance & Momentum

6 Months 32.71 %

1 Year 1,257 %

3 Years 351.02 %

5 Years 239.42 %

Momentum

Unlock this indicator

Recent News

Terns Pharmaceuticals Inc

Terns Pharmaceuticals surges on positive TERN-701 Phase 1 data

7 months ago

In October 2025, Terns Pharmaceuticals reported highly positive Phase 1 results for its TERN-701 treatment targeting chronic myeloid leukemia (CML). The study showed a major molecular response rate of 75% at 24 weeks with good tolerance and no dose-limiting toxicity. These promising data, selected for an oral presentation at a major hematology conference, signal a strategic shift for the company from metabolic disorders to oncology. Additionally, stock options were granted to new employees under an incentive plan, indicating strong internal momentum. This clinical success may boost Terns' market valuation and attract investor interest in its CML treatment prospects.

source: anantys.com • medicine, oncology, clinical trials

Strategic Analysis

Terns Pharmaceuticals is positioned as an innovative player in biotechnology, focused on developing cutting-edge therapies in hepatology, particularly for the treatment of NASH, a disease with a significant unmet medical need. Its model is based on targeted research and advanced clinical development, offering differentiated potential in a high-growth segment.

Strengths

Deep expertise in hepatology and liver diseases
Strong valuation growth reflecting increased market confidence
Positioning in a rapidly expanding addressable market

Weaknesses

Dependence on clinical outcomes and regulatory approvals
Lack of geographic or sector diversification

Momentum

Exceptional momentum reflects strong investor enthusiasm, driven by promising progress in its clinical programs and disruptive potential in the treatment of NASH. This dynamic supports high visibility, but also calls for caution regarding the delivery of expected results.

Analysis performed 2 months ago